Key Highlights

  • Fiscal fourth quarter Revenue rose 5.5% to USD 88.4 billion, ahead of the USD 87.95 billion estimate.
  • Adjusted EPS of USD 4.66 beat the USD 4.58 estimate, while GAAP EPS was USD 2.71.
  • Fiscal 2027 adjusted EPS is guided to USD 19.40 to USD 19.75, against USD 17.97 this year.
  • The quarterly Dividend rises 10% to USD 0.66 per share from USD 0.60, payable on November 30, 2026.

Cencora (NYSE:COR) reported revenue of USD 88.4 billion for the fiscal fourth quarter ended September 30, 2026, up 5.5% and above the USD 87.95 billion estimate. Adjusted diluted EPS rose 21.4% to USD 4.66 from USD 3.84, compared with the USD 4.58 estimate. GAAP diluted EPS was USD 2.71, against a loss of USD 1.75 a year earlier, when a USD 723.9 million PharmaLex Goodwill Impairment weighed on results.

Segments and Margin Drivers

U.S. Healthcare Solutions revenue was USD 78.3 billion, up 5.4%, on unit Volume growth that included specialty products and GLP-1 medicines, partly offset by lower manufacturer prices on some Brand drugs and reduced sales to a large mail order customer. Segment Operating Income rose 22.0% to USD 997.6 million. International Healthcare Solutions revenue was USD 7.8 billion, up 5.1%, or 7.8% in constant currency, with operating income up 16.4% to USD 152.1 million.

Other businesses generated USD 2.3 billion of revenue, up 10.1%, with operating income of USD 101.1 million, up 35.8%. Adjusted Gross Profit rose 23.0% to USD 3.6 billion, and the adjusted gross margin was 4.04%, up 57 basis points, mainly because of the February 2026 OneOncology acquisition, partly offset by lower-margin GLP-1 sales.

Adjusted operating income increased 22.1% to USD 1.2 billion, a 1.41% margin. Net interest expense rose USD 58.5 million to USD 136.3 million after Acquisition financing. The adjusted tax rate was 20.2%, while the GAAP rate was 32.8% because of discrete tax items. Net Income attributable to Cencora was USD 519 million on a GAAP basis and USD 893 million adjusted.

Full Year Results and Corporate Actions

Fiscal 2026 revenue rose 5.0% to USD 337.4 billion. Adjusted diluted EPS increased 12.3% to USD 17.97, and GAAP diluted EPS rose 125.5% to USD 17.95. Chief executive Robert Mauch called the year pivotal, citing the OneOncology deal and a sharper portfolio.

Cencora signed an agreement to acquire American Oncology Network, a physician-led network of more than 350 providers across 21 states, and agreed to sell its Profarma stake, with closing scheduled for the first quarter of fiscal 2027. The board declared a USD 0.66 quarterly dividend payable November 30, 2026. Beginning in fiscal 2027, reporting moves to Pharmaceutical Distribution and Services and Specialty Pharmaceutical and Provider Services, with Other outside the reportable segments.

Fiscal 2027 Guidance

Cencora guided fiscal 2027 adjusted diluted EPS to USD 19.40 to USD 19.75, growth of 8% to 10%. Revenue is guided to growth of 3% to 5%, and adjusted operating income to growth of 4% to 6%. By segment, Pharmaceutical Distribution and Services revenue is guided up 4% to 6%, and Specialty Pharmaceutical and Provider Services revenue up 9% to 14%, with operating income up 18% to 21%.

Other assumptions include net interest expense of USD 490 million to USD 510 million, an adjusted tax rate near 20%, about 190 million diluted shares, adjusted free Cash Flow near USD 3.5 billion and capital expenditures near USD 1.0 billion. The outlook assumes the Profarma sale closes in the first fiscal quarter and the MWI Animal Health Merger with Covetrus closes on March 31, 2027.

Key Figures Side by Side

Fourth quarter adjusted EPS of USD 4.66 compares with fiscal 2026 adjusted EPS of USD 17.97 and a fiscal 2027 guide of USD 19.40 to USD 19.75. Adjusted free cash flow of USD 3.8 billion in fiscal 2026 compares with a guide near USD 3.5 billion, while capital expenditures of USD 910 million compare with a guide near USD 1.0 billion. Fourth quarter GAAP EPS of USD 2.71 compares with adjusted EPS of USD 4.66.